ATI-052 Phase 1b POC Results Update - ACLARIS THERAPEUTICS INC

Financial Performance:

• The company raised a $50 million top-up financing, extending its cash runway from the end of 2028 to mid-2029.
• No specific revenue, GAAP/Non-GAAP earnings, or debt figures were disclosed, as the company remains in clinical development (Phase 1B).
• Cash utilization is prioritized for the EOE Phase IIb/III program, Lichen Planus oral cohort, and ITK inhibitor programs.

Guidance and Future Outlook:

• Prioritized EOE (Eosinophilic Esophagitis) as the next indication for ATI-052, with a seamless Phase IIb/III trial expected to start in early 2027.
• Anticipate top-line data for the T-slip mAb (Bosacatug) in AD later in the current quarter.
• Plan to initiate the Lichen Planus (LP) trial in the coming weeks, with an interim analysis expected in late 2027 for potential FastTrack registration conversion.
• Expect to file an IND for the ITK inhibitor (ETI-9494) this quarter, launching further catalysts in 2027.
• Evaluating a potential fourth indication for ATI-052, though EOE remains the primary focus for capital allocation.

Business Segments and Product Lines:

• ATI-052 (Bispecific): Demonstrated proof of concept in Atopic Dermatitis (AD) and Asthma; targets T-slip (upstream) and IL-4R/IL-13 (downstream).
• AD Results: In a severe, diverse population (82% IGA-4), 5 weekly loading doses resulted in 45% placebo-adjusted EASI improvement at Week 8, with 78% of patients achieving EASI-50. Response maintained through Week 16 (12 weeks post-last dose).
• Asthma Results: A single dose (480mg) in mild-to-moderate patients yielded 59% reduction in FeNO and significant FEV1 improvements (up to 350mL absolute improvement in the low-function subset) within 2 weeks.
• Biomarkers: Achieved complete normalization of the skin proteome in AD patients (95% improvement vs. non-lesional) and reduced Th1, Th2, Th17, and Th22 signatures.
• Bosacatug: T-slip specific mAb; Phase 2A data showed durability up to 4-5 months post-dose.
• Monzatinib: Oral small molecule T2 inhibitor; received FastTrack designation; Phase 2 LP trial starting soon.
• ETI-9494: Next-gen ITK inhibitor; IND filing imminent.

Market and Competitive Landscape:

• AD: Addresses a massive, growing market with high unmet need for higher efficacy and broader endotype coverage than Dupilumab (which blocks only IL-4R/IL-13).
• Asthma: Targets T2-high and T2-low populations; aims to improve upon Dupilumab's profile in patients with lower eosinophil counts (<300 cells/µL).
• EOE: Sees the market as "white space" with ample opportunity, leveraging validation from Tesidolumab and Dupilumab but aiming for best-in-class T-slip potency.
• Differentiation: ATI-052's dual mechanism targets Th17 and Th1 skewing not addressed by IL-4R blockade alone, potentially offering deeper efficacy across diverse patient subgroups.

Risks and Challenges:

• Safety: While no conjunctivitis was observed (a differentiator from Dupilumab), long-term safety remains to be confirmed in larger trials.
• Development Complexity: Managing multiple clinical programs (ATI-052 in EOE, AD, Asthma; Monzatinib in LP; ETI-9494) requires disciplined capital allocation.
• Dosing Optimization: Determining the optimal induction and maintenance dosing regimens to achieve quarterly dosing while maintaining efficacy is ongoing.
• Regulatory Path: Reliance on interim analyses and FastTrack conversion for Lichen Planus introduces regulatory execution risk.

Management Commentary and Tone:

• Management expressed high confidence ("compelling proof of concept," "art of the possible," "real opportunity to raise the ceiling") regarding the additive/synergistic effects of the dual mechanism.
• Tone is optimistic yet pragmatic, emphasizing capital efficiency and the strategic shift to EOE to maximize the probability of success for the company.
• CEO Neil Walker highlighted the "disciplined capital allocation" strategy, prioritizing EOE for its lower capital intensity and clear path to registration compared to AD or Asthma.

Analyst Questions and Answers:

• Safety Profile: Analysts asked about safety advantages vs. Dupilumab; management confirmed no conjunctivitis and noted broader immune suppression (Th1/Th17) may mitigate Th17 skewing issues.
• Dosing Frequency: Discussion focused on achieving quarterly dosing; management believes 4-week intervals are feasible for AD and potentially easier for EOE, contrasting with Dupilumab's bi-weekly or weekly schedules.
• EOE Trial Design: Confirmed a seamless Phase IIb/III design focusing on histological remission as a sensitive endpoint, with potential for registration conversion if data supports.
• LP Trial: Confirmed a basket study design starting with the oral mucosal cohort, using ODSS (Oral Disease Severity Score) as the primary endpoint.
• Capital Usage: The $50M raise fully funds the EOE program, LP trial, and ITK program, extending the runway by two quarters.
• Durability: Confirmed zero patients in the active AD group required rescue medication, supporting the durability hypothesis of the T-slip component.

Other Key Points:

• Patient Demographics: The AD trial enrolled a highly severe (78% IGA-4) and diverse population (significant Black/Asian representation), which typically presents challenges for Th2-only therapies.
• Biomarker Depth: Tape strip proteomics showed ATI-052 shifted lesional skin profiles to closely resemble non-lesional skin, a 95% improvement compared to 66% reported for Dupilumab in comparable metrics.
• Conjunctivitis: Explicitly noted as a major differentiator, with zero cases reported across all ATI-052 clinical studies to date.
• Mechanism Validation: Data reinforces the critical role of T-slip in AD, evidenced by reductions in IL-5, eosinophils, and Th1 biomarkers that IL-4R blockade alone does not address.